Proposed US legislation aimed at patent thickets unlikely to boost biologics competition
The Biologic Patent Transparency Act seeks to accelerate biosimilar entry, but leaves key litigation issues unaddressed and would confer only marginal benefits on imitators
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.